DiaPep 277
Also known as: DiaPep277, hsp60 p277, Hsp60‑277 peptide, p277
Source DiaPep 277 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
DiaPep277 is a synthetic 20‑amino‑acid peptide (residues 277‑296 of human heat‑shock protein 60) investigated as an antigen‑specific immunotherapy to preserve pancreatic β‑cell function in newly diagnosed type 1 diabetes.
Mechanism of Action
Derived from Hsp60; modulates autoimmune response by inducing regulatory T cells and reducing beta‑cell specific autoimmunity in type 1 diabetes.
Routes of Administration
Goals & Uses
- Reduction of exogenous insulin requirementsMetabolicLow
- Preservation of beta-cell function in type 1 diabetesAutoimmune / EndocrineModerate
- Reduce exogenous insulin requirementClinical OutcomeModerate
- Preserve C‑peptide secretionDisease ModificationModerate
- Immune tolerance inductionImmunologyLow
Contraindications
- Known hypersensitivity to DiaPep277 or any formulation componentAllergyHigh
- Immunosuppressive therapyPharmacologicalModerate
- Known hypersensitivity to peptide componentsAllergyHigh
- Active systemic infectionInfectiousModerate
Adverse Effects
- Hypersensitivity reactionsImmunologicRare
- Flu-like symptomsSystemic/ImmunologicalUncommon
- Injection site reactionsLocalCommon
- Transient flu‑like symptomsSystemicUncommon
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Immunosuppressants (e.g., corticosteroids, azathioprine)Moderate
- Other immunomodulatory biologicsModerate
- Immunosuppressants (e.g., tacrolimus)Moderate
Population Constraints
- Long-standing type 1 diabetes with no residual beta-cell functionDisease SpecificAbsolute
- Pediatric patients (<18 years)AgeRelative
- Children <12 yearsAgeRelative
- Pregnancy and lactationReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trial status; not authorized for marketing.
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
- United KingdomUnapprovedNo approval sought or granted in the UK.
Phase III trials did not meet primary endpoints; not approved in any jurisdiction and no commercial product exists.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is DiaPep 277?
DiaPep277 is a synthetic 20‑amino‑acid peptide (residues 277‑296 of human heat‑shock protein 60) investigated as an antigen‑specific immunotherapy to preserve pancreatic β‑cell function in newly diagnosed type 1 diabetes.
What is DiaPep 277 used for?
DiaPep 277 is educationally associated with: Reduction of exogenous insulin requirements, Preservation of beta-cell function in type 1 diabetes, Reduce exogenous insulin requirement, Preserve C‑peptide secretion, Immune tolerance induction. Educational only — not medical advice.
How is DiaPep 277 administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of DiaPep 277?
Reported adverse effects include: Hypersensitivity reactions, Flu-like symptoms, Injection site reactions, Transient flu‑like symptoms, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid DiaPep 277?
Recorded contraindications: Known hypersensitivity to DiaPep277 or any formulation component, Immunosuppressive therapy, Known hypersensitivity to peptide components, Active systemic infection. Consult a qualified clinician before use.